Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous immunoglobulin (IGIV-C) for efficacy and safety in symptomatic generalized myasthenia gravis has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis Generalized

Drugs mentioned

• IGIV-C

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Myasthenia Gravis, Generalized | Phase 2 | Status: COMPLETED | Results posted: 2019-03-05